Category: Alzheimer’s Disease

Hyperbaric chambers have been posited as a means of solving one of medicine’s great challenges.

By Tim Kiek

Therapy mimics state of ‘hypoxia’ and is similar to that employed by deep-sea divers.

Alzheimer’s disease can be effectively treated by giving oxygen to patients in pressurised chambers, a study from Tel Aviv University suggests.

Over the course of three months, for 90 minutes a day, five days a week, six elderly patients exhibiting the early signs of dementia were administered oxygen in a hyperbaric chamber.

Researchers said the results showed blood flow increased to the triallists’ brains from 16 per cent to 23 per cent and all demonstrated significantly improved brain function.

Memory test scores increased by 16.5 per cent, attention by six per cent, and information processing speeds by 10.3 per cent.

The chamber works by mimicking the state of oxygen shortage or ‘hypoxia’, effectively changing the structure of vessels in the brain. This means that when those in the chamber are fed oxygen, their tissue absorbs it at a faster rate and in a greater volume.

Continue reading… “Alzheimer’s can be ‘stalled or reversed’ using oxygen”

An international research team led by scientists from the Hong Kong University of Science and Technology (HKUST) has developed a novel strategy using brain-wide genome-editing technology that can reduce Alzheimer’s disease (AD) pathologies in genetically modified AD mouse models. This advanced technology offers immense potential to be translated as a novel long-acting therapeutic treatment for AD patients.

In China alone, over 500,000 patients are estimated to be living with a hereditary form of AD — familial Alzheimer’s disease (FAD), which is a congenital form of AD highly associated with family history. Although FAD has a clear genetic cause and can be diagnosed before cognitive problems occur, no effective treatment currently exists.

There is enormous potential in the use of genome-editing technology* as therapeutic strategies for diseases caused by inherited mutations, such as FAD. It is especially useful for correcting disease-causing genetic mutations before symptoms appear, for which it is considered a “once-and-for-all” treatment as its effects can last a lifetime. However, several hurdles have prevented its clinical development and application — most notably the lack of an effective, efficient, and non-invasive means to deliver genome-editing agents into the brain. Furthermore, existing genome-editing technologies are unable to generate beneficial outcomes throughout the whole brain.

Continue reading… “Genome-editing strategy developed for potential Alzheimer’s therapy”